Replimune Group (REPL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Jul, 2026Executive summary
Annual meeting scheduled for September 15, 2026, to be held virtually at 8:30 A.M. Eastern time.
Proxy materials and annual report for the fiscal year ended March 31, 2026, are available online for review and voting.
Shareholders are encouraged to vote online or request paper copies of proxy materials by August 31, 2026.
Voting matters and shareholder proposals
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending March 31, 2027.
Advisory vote to approve executive compensation for the fiscal year ended March 31, 2026.
Proposal to amend the certificate of incorporation to increase authorized common stock from 150,000,000 to 300,000,000 shares.
Audit committee and external auditor matters
Board recommends ratifying PricewaterhouseCoopers LLP as the independent registered public accounting firm for the next fiscal year.
Latest events from Replimune Group
- FDA accelerated approval of TUDRIQEV plus nivolumab offers new hope for advanced melanoma post-PD-1.REPL
FDA announcement6 Aug 2026 - A novel oncolytic virus plus nivolumab shows strong efficacy and safety in advanced melanoma.REPL
Investor presentation6 Aug 2026 - Stockholders will vote on auditor ratification, executive pay, and doubling authorized shares.REPL
Proxy filing29 Jul 2026 - Registering 25.1M shares for resale, the company faces regulatory and financial uncertainty.REPL
Registration filing24 Jul 2026 - Stockholders will vote on auditor ratification, executive pay, and doubling authorized shares.REPL
Proxy filing13 Jul 2026 - Directors were elected, key proposals passed except the incentive plan amendment.REPL
AGM 20259 Jul 2026 - RP1 plus nivolumab achieved a 33.6% ORR and durable responses in anti-PD1 failed melanoma.REPL
Study Result9 Jul 2026 - RP1 shows 34% response in anti-PD-1 failed melanoma, with global launch and expansion planned.REPL
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - FDA accepted RP1 BLA resubmission; cash funds operations into 2027; strong clinical results.REPL
Q4 202629 Jun 2026